BG
ALNY icon

BlackRock Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlackRock Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$8.91M Sell
237,918
-274,177
-54% -$11.5M ﹤0.01% 953
2016
Q3 		$34.7M Sell
512,095
-45,363
-8% -$3.2M 0.02% 670
2016
Q2 		$30.9M Buy
557,458
+37,624
+7% +$2.37M 0.02% 681
2016
Q1 		$32.6M Buy
519,834
+93,450
+22% +$6.21M 0.02% 680
2015
Q4 		$40.1M Buy
426,384
+10,479
+3% +$972K 0.02% 633
2015
Q3 		$33.4M Buy
415,905
+146,528
+54% +$16.3M 0.02% 665
2015
Q2 		$32.3M Buy
269,377
+189,632
+238% +$22.7M 0.02% 698
2015
Q1 		$8.33M Buy
79,745
+42,120
+112% +$4.27M ﹤0.01% 1004
2014
Q4 		$3.65M Buy
37,625
+8,060
+27% +$747K ﹤0.01% 1223
2014
Q3 		$2.31M Sell
29,565
-33,001
-53% -$2.13M ﹤0.01% 1363
2014
Q2 		$3.95M Buy
62,566
+19,196
+44% +$1.14M ﹤0.01% 1204
2014
Q1 		$2.91M Buy
43,370
+10,351
+31% +$801K ﹤0.01% 1349
2013
Q4 		$2.12M Sell
33,019
-321,767
-91% -$19.2M ﹤0.01% 1490
2013
Q3 		$22.7M Buy
354,786
+15,678
+5% +$781K 0.02% 734
2013
Q2 		$10.5M Buy
+339,108
New +$9.02M 0.01% 848

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's ALNY Position: Q4 2016 in Review

BlackRock Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 54% in Q4 2016, selling an estimated $11.5M and leaving 237,918 shares worth $8.91M. The position accounts for ﹤0.01% of the portfolio, ranked #953.

BlackRock Group first reported a position in ALNY in Q2 2013 and has held it in 15 quarters since. The position peaked at $40.1M in Q4 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • BlackRock Group held 237,918 shares of Alnylam Pharmaceuticals worth $8.91M as of Q4 2016.
  • BlackRock Group sold 274,177 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $11.5M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #953 holding.
  • BlackRock Group first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Alnylam Pharmaceuticals position peaked at $40.1M in Q4 2015.
  • 211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.